Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Palatin Technologies (PTN)

Palatin Technologies Inc New
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:PTN
DateTimeSourceHeadlineSymbolCompany
17/07/202416:14Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]AMEX:PTNPalatin Technologies Inc New
16/07/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
16/07/202421:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
21/06/202413:00PR Newswire (US)Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsAMEX:PTNPalatin Technologies Inc New
20/06/202412:30PR Newswire (US)Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)AMEX:PTNPalatin Technologies Inc New
12/06/202412:30PR Newswire (US)Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
15/05/202413:40Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
15/05/202413:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:PTNPalatin Technologies Inc New
15/05/202412:30PR Newswire (US)Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAMEX:PTNPalatin Technologies Inc New
09/05/202412:30PR Newswire (US)Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024AMEX:PTNPalatin Technologies Inc New
02/05/202412:30PR Newswire (US)Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityAMEX:PTNPalatin Technologies Inc New
30/04/202412:30PR Newswire (US)Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024AMEX:PTNPalatin Technologies Inc New
08/04/202412:30PR Newswire (US)Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024AMEX:PTNPalatin Technologies Inc New
07/03/202422:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:PTNPalatin Technologies Inc New
04/03/202417:57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesAMEX:PTNPalatin Technologies Inc New
28/02/202412:30PR Newswire (US)Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
15/02/202414:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
15/02/202412:30PR Newswire (US)Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateAMEX:PTNPalatin Technologies Inc New
14/02/202421:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:PTNPalatin Technologies Inc New
14/02/202419:55Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:PTNPalatin Technologies Inc New
09/02/202412:30PR Newswire (US)Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024AMEX:PTNPalatin Technologies Inc New
05/02/202412:30PR Newswire (US)Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)AMEX:PTNPalatin Technologies Inc New
01/02/202422:16Edgar (US Regulatory)Form 8-K - Current reportAMEX:PTNPalatin Technologies Inc New
01/02/202421:00PR Newswire (US)Palatin Announces Closing of $10 Million Registered Direct OfferingAMEX:PTNPalatin Technologies Inc New
 Showing the most relevant articles for your search:AMEX:PTN